| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 954 | 1,122 | ||
| General and administrative | 1,135 | 986 | ||
| Total operating expenses | 2,089 | 2,108 | ||
| Loss from operations | -2,089 | -2,108 | ||
| Interest income | -22 | -28 | ||
| Foreign exchange gain (loss) | 18 | 25 | ||
| Total other income, net | 40 | 53 | ||
| Net loss | -2,049 | -2,055 | ||
| Net loss per common share, basic | -0.19 | -0.2 | ||
| Net loss per common share, diluted | -0.19 | -0.2 | ||
| Weighted average number of common shares, basic | 10,991,000 | 10,174,000 | ||
| Weighted average number of common shares, diluted | 10,991,000 | 10,174,000 | ||
Cocrystal Pharma, Inc. (COCP)
Cocrystal Pharma, Inc. (COCP)